Fintech PR

March – Introduce More Carrots in Your Diet

Published

5 years ago

March 26, 2019

Reading Time: 5 minutes

Although carrots are available throughout the year, carrots grown at local, seasonal, summer and autumn season are more preferable because they are fresher and more delicious. Carrots are part of the Umbelliferae family, called after-umbrella, like clusters of flowers radiates from a single point. Per se, carrots are closely related as a family of, fennel, parsley, anise, cumin, caraway and dill.

We are fortunate to have the results of a new 10-year study in the Netherlands with carrots and the risk of cardiovascular disease (CVD) – and these results are really fascinating. The fruit and vegetable input in the study was classified by color and focused on four color categories: green, orange / yellow, red / violet, white. Of these four categories, orange / yellow (and, in particular, deep orange and yellow foods) have been the most beneficial and protective against cardiovascular diseases. Participants who ate at least 25 grams of carrots (25 grams, less than one quarter of a cup) had a significantly lower risk of CVD. Groups of participants who ate 50 or 75 grams more had an even lower risk of CVD!

Much of the research has focused on carotenoids in carrots and their important antioxidant benefits. After all, carrots (along with pumpkin and spinach) have a high ranking on the list of legumes considered antioxidants, commonly consumed in the US. But recent studies have come to the conclusion and brought the carrot as a part of nutrients called phytonutrients. In carrots, the most important components are polyacetylenes, falcarinol and falcarindiol. Several recent studies have identified these polyacetylenes in carrot as phytonutrients that can help inhibit the growth of colon cancer cells. These new findings are exciting because they suggest a key interaction between carotenoids and polyacetylenes carrots. Apparently, rich carotenoid content in carrots helps prevent oxidative damage not only inside our body but can also help prevent oxidative damage. In other words, these two stunning groups of carrot phytonutrients can work together in a synergistic way to maximize their benefits in our health!

Carrots have been found to have a better taste, while cooked steam! In a recent study on examining different methods in cooking vegetables, study participants were asked to evaluate the flavor and taste, the overall acceptability of the results. Compared with boiling points, study participants significantly favored the general taste and acceptability of steamed carrots, as compared to boiled ones.

Raw Carrots, slices

1.00 cup

(122.00 grams) Calories: 50

GI: low

NutrientDRI / DV

– vitamin A113%, biotin20%, vitamin K18%, fibre14%, molybdenum14%, potassium11%, vitamin C10%, vitamin B610%, mangan9%, vitamin B38%, vitamin B17%, pantothenic acid7%, copper6, phosphorus6%, folate6%, vitamin B25%, vitamin E5%

Carrots are probably best known for providing rich nutrients and antioxidants, which was actually called: beta-carotene. However, these delicious root vegetables are the source of not only beta-carotene, but also contain a wide variety of antioxidants and other nutrients. They are beneficial in cardiovascular problems but are also anti-cancer nutrients.

Antioxidant benefits

All carrot varieties contain significant amounts of antioxidant nutrients. Included here are traditional antioxidants, such as vitamin C, as well as phytonutrient antioxidants such as beta-carotene. The list includes:

carotenoids

alpha-carotene

beta-carotene

lutein

Hydroxycinnamic acids

caffeic acid

Coumaric acid

Ferulic acid

Anthocyanidins

cyanidins

malvidin

Different varieties of carrots contain different amounts of these antioxidant phytonutrients. Red and purple carrots, for example, are best known for their rich anthocyanin content. The oranges are particularly remarkable in terms of beta-carotene content, which accounts for 65% of their total carotenoid content. In yellow carrots, 50% of all carotenoids come from lutein.

Cardiovascular benefits

Given their richness in antioxidants, it is not surprising to find many studies about it. Our cardiovascular system needs constant protection. Thus they (carrots) are considered cardioprotective.

The anti-cancer benefits

The anti-cancer benefits of carrot have been proven in the prevention and treatment of colon cancer. Part of this research involved the actual intake of carrot juice by the participants, as well as other research that involved studies on different types of cancer cells.

“Baby” carrots are rich in nutrients and low in calories and are ideal for raw or steam snacks or in a mixture of vegetables.

What do they contain?

Vitamin A

Vitamin A is the nutrient found in carrots of all types and varieties. Each minced “cup” contains 21384 IUs – international units. The daily dose, for example recommended for women, is 2,300 IU, or 700 micrograms. Vitamin A helps ensure good vision, healthy skin and proper functioning of the immune system. For the reproduction of a cell, we need vitamin A, but it also participates in bone formation. Vitamin A in carrot comes in the form of beta-carotene, which the body turns into vitamin A during digestion. Although carrot consumption is beneficial, taking large amounts of vitamin A through supplements can cause toxicity.

Fiber

A cup of baby-chopped carrots or large carrots contains 3.6 grams of dietary fiber, which is up 10 percent of the amount we need in a day. Fiber supports digestion, regland and helping constipated people. Fiber-rich diets are also linked to lowering cholesterol levels, reducing the risk of diabetes and preventing colon cancer. Foods rich in fiber are also useful for weight control, adding the amount of free calories to food.

Vitamin K

Vitamin K is an essential vitamin that plays a role in blood clotting and the production of certain bone proteins. A cup of baby-carrots or chopped carrots contains about 17 micrograms of vitamin K; adult women need 90 micrograms per day. Other excellent sources of vitamin K are everything that is green and dark green, leaves such as cabbage, spinach, and broccoli and soybean oil. If you take any anticoagulant, such as warfarin, it can not be taken safely with large amounts of vitamin K.

C vitamin

At 7.6 milligrams of vitamin C per cup of minced carrots, carrots provide about 10 per cent of the 75 milligram daily needed for women. Our body uses vitamin C for a lot of functions, including immune support, cell repair and wound healing. Vitamin C also helps you absorb iron from food, which is especially important for menstruation in women. However, there is no truth in that myth, which tells us that consuming large amounts of vitamin C helps prevent colds. Although vitamin C supplements can regularly reduce the duration of colds. They play an important role in cancers and tumors, being antitumor, and yes they play an important role in fighting various viruses and bacteria, etc.

Our carrot vegan cream soup contains:

A bigger handful of baby carrots, a tiny root of parsley, a half of white onion (or leeks), 1 tablespoon organic coconut butter, a little Himalayan salt, spring water – mix together in the blender and get serve with dry mint (vegetables can boil light in steam, or you can make the soup in their raw state)

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024

Published

2 weeks ago

April 5, 2024

CISION (PR Newswire)

STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826

The following files are available for download:

https://mb.cision.com/Main/87/3956826/2712771.pdf	Invitation to presentation of EQT AB’s Q1 Announcement 2024
https://news.cision.com/eqt/i/eqt-ab-group,c3285895	EQT AB Group

View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs

Published

2 weeks ago

April 5, 2024

CISION (PR Newswire)

kia-presents-roadmap-to-lead-global-electrification-era-through-evs,-hevs-and-pbvs

Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Published

2 weeks ago

April 5, 2024

CISION (PR Newswire)

VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html